RxDoctor Payments Data

Anupam Sidhu, MD

Family Medicine · Houston, TXNPI 1154523488

Payments from drug & device makers

$2,728in general payments, 2019–2025

Across 135 payments — averaging $20.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$566
  • Lilly USA, LLC$252
  • Pfizer$242
  • Supernus Pharmaceuticals, Inc.$234
  • AbbVie$132
  • Amgen$120
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$2,728100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,728 in reported general payments places this provider in the 75th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$92,416
Medicare patients
155
Services billed
3,681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide21$23,746
OzempicSemaglutide20$22,062
JardianceEmpagliflozin15$16,164
JanuviaSitagliptin Phosphate12$13,671
TradjentaLinagliptin11$12,258
EliquisApixaban14$9,590
ShingrixVaricella-Zoster Ge/As01b/Pf24$5,262
SynthroidLevothyroxine Sodium22$1,972
Rosuvastatin Calcium70$1,422
Nateglinide22$1,402
Levothyroxine Sodium146$1,394
Pantoprazole Sodium80$1,290
Atorvastatin Calcium132$1,161
Nifedipine ErNifedipine21$1,053
Memantine Hcl12$1,026

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$37$28,42226 claims
Lilly USA, LLCTrulicity$252$23,74621 claims
Novo NordiskOzempic$566$22,06220 claims
MerckJanuvia$50$13,67112 claims
PfizerEliquis$242$9,59014 claims
GSKShingrix$102$5,26224 claims
AbbVieSynthroid$132$1,97222 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$13$1,394146 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →